Clinical trials: Amlodipine
Hypertension
Effect of the Fixed Dose Combination Amlodipine/Valsartan on Central Aortic Blood Pressure in Uncontrolled Essential Hypertension With Amlodipine 5 mg
Assess that for an equivalent brachial blood pressure (BP)lowering, a fixed dose combination amlodipine/valsartan based regimen reduces central aortic BP pressure to a larger extent than an atenolol/amlodipine combination based…
- Trial name
- EXPLOR (NCT00687973)
- Testing
- Valsartan/amlodipine 80/5 mg tablets, Amlodipine 5 mg capsules, Amlodipine 10 mg capsules
- Where
- France
- Volunteers
- 393 people
- Sponsor
- Novartis Pharmaceuticals
Healthy Subjects
Bioequivalence Study of CJ-30060 in Healthy Volunteers
To compare the pharmacokinetics and safety after a single dose administration of CJ-30060 and Exforge® 5/160mg, Crestor® 10mg in healthy volunteers.
- Trial name
- NCT03757390
- Testing
- Exforge® tab 5/160mg, Crestor® tab 10mg, CJ-30060 5/160/10mg
- Where
- South Korea
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- HK inno.N Corporation
Healthy
Bioavailability of Telmisartan/Amlodipine Fixed-dose Combination Compared to Its Mono-components in Healthy Male Volunteers
Study to investigate the relative bioavailability of fixed-dose combination tablet vs. mono-components of telmisartan and amlodipine
- Trial name
- NCT02259790
- Testing
- Telmisartan/amlodipine fixed-dose combination tablet, Telmisartan, Amlodipine
- Volunteers
- 30 people
- Sponsor
- Boehringer Ingelheim
Essential Hypertension, Hyperlipidemia
Study to Investigate the Effect of Telmisartan/S-amlodipine on the Pharmacokinetic Properties of Atorvastatin.
The purpose of this study is to investigate the effect of telmisartan/s-amlodipine on the pharmacokinetic properties of atorvastatin.
- Trial name
- CKD-345 (NCT01842256)
- Testing
- Telmisartan 80mg, S-amlodipine 5mg and Atorvastatin 40mg, atorvastatin 40mg
- Where
- South Korea
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Hypertension
CKD-828 (80/5mg) Pharmacokinetic Study
A randomized, open-label, single-dose, two-period, two-way, crossover study to compare the pharmacokinetics and safety CKD-828 (Fixed Dose Combination Tablet) to coadministration telmisartan and s-amlodipine in health volunteers.
- Trial name
- NCT02250833
- Testing
- CKD-828, Telmisartan, S-amlodipine
- Where
- South Korea
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Hypertension
26-week Open Study of telmisartan40mg+amlodipine10mg or telmisartan80mg+amlodipine10 mg in Hypertension
The primary objective of this trial is to assess the efficacy and safety of the fixed dose combinations telmisartan 40mg/amlodipine 10mg (T40/A10) or telmisartan 80mg/amlodipine 10mg (T80/A10) during open-label treatment for at…
- Trial name
- NCT00624052
- Testing
- fixed-dose combination of telmisartan 40mg+amlodipine 10mg, fixed-dose combination of telmisartan 80mg+amlodipine10mg
- Where
- 92 sites in Australia, Austria and 10 more
- Volunteers
- 838 people
- Sponsor
- Boehringer Ingelheim
Hypertension
Study to Evaluate the Pharmacokinetic Interaction and Safety After Multiple Oral Doses of Fimasartan/Amlodipine and Rosuvastatin in Healthy Male Subjects
An Open-label, Fixed-sequence, Crossover Study to Evaluate the Pharmacokinetic Interaction and Safety after multiple oral doses of Fimasartan/Amlodipine and Rosuvastatin in Healthy Male Subjects.
- Trial name
- NCT02397538
- Testing
- Fimasartan, Amlodipine, Rosuvastatin
- Where
- South Korea
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Hypertension
Add-on to Micamlo BP Trial
This is a multi-centre, randomised, double-blind, active-controlled, parallel-group comparative trial to compare the fixed dose combination (FDC) of telmisartan 80 mg +hydrochlorothiazide 12.5 mg and amlodipine 5 mg (T80/A5/H12.5…
- Trial name
- NCT01975246
- Testing
- Telmisartan + amlodipine, hydrochlorothiazide
- Where
- 30 sites in Japan
- Volunteers
- 309 people
- Sponsor
- Boehringer Ingelheim
Hypertension
Efficacy/Safety of Amlodipine Plus Losartan Versus Losartan in Patients With Essential Hypertension
The purpose of this study is to evaluate of efficacy and safety of amlodipine plus losartan and losartan alone in patients with essential hypertension inadequately controlled on losartan monotherapy.
- Trial name
- NCT00940680
- Testing
- Amlodipine plus Losartan, Losartan
- Where
- South Korea
- Volunteers
- 142 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Hypertension
Compare Efficacy and Safety of Telmisartan/Hydrochlorothiazide With Telmisartan/Hydrochlorothiazide Plus Amlodipine
This is a multi-centre, randomised, double-blind, active-controlled, parallel-group comparative trial to compare the fixed dose combination (FDC) of telmisartan 80 mg + hydrochlorothiazide 12.5 mg and amlodipine 5 mg…
- Trial name
- NCT01911780
- Testing
- telmisartan + HCTZ, amlodipine
- Where
- 17 sites in Japan
- Volunteers
- 132 people
- Sponsor
- Boehringer Ingelheim
Hypertension
Efficacy and Safety of TELMINUVO to Stage 2 Hypertension
The aim of present study is to evaluate the efficacy and safety of two dose combination of Telmisartan/S-Amlodipine (80/2.5mg and 80/5mg) compared with S-Amlodipine monotherapy (2.5mg and 5mg) in patients with Stage 2…
- Trial name
- NCT01983735
- Testing
- TELMINUVO Tab. (80/2.5mg), TELMINUVO Tab. (80/5mg), S-amlodipine 2.5mg
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Hypertension, Chronic Stable Angina
Bioequivalency Study of Amlodipine Tablets Under Fasting Conditions
The objective of this study was the bioequivalence of a Roxane Laboratories' Amlodipine Besylate tablets, 10 mg, to Norvasc® Tablets, 10 mg (Pfizer) under fasting conditions using a single-dose, randomized, 2-treatment, 2-period…
- Conditions
- Hypertension, Chronic Stable Angina, Vasospastic Angina
- Trial name
- NCT00602017
- Testing
- Amlodipine
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Roxane Laboratories
Essential Hypertension
Efficacy and Safety of SPA100 (Fixed-dose Combination of Aliskiren/Amlodipine) in Patients With Essential Hypertension
The purpose of the study was to evaluate the efficacy (blood pressure lowering effect) and safety of SPA100 (Fixed-dose Combination of Aliskiren and Amlodipine) in patients with essential hypertension (mean sitting diastolic…
- Trial name
- NCT01237223
- Testing
- Aliskiren/Amlodipine 150/2.5 mg, Aliskiren/amlodipine 150/5 mg, Aliskiren 150 mg
- Where
- 11 sites in Japan
- Volunteers
- 1,342 people
- Sponsor
- Novartis
Hypertension, Cardiovascular Diseases (CVD)
VITAL: Real-World Evaluation of Amlodipine/Valsartan.
The goal of this observational study is to evaluate the effectiveness, safety, and treatment adherence of a fixed-dose combination of amlodipine and valsartan in adults with grade 2-3 hypertension in real-world clinical practice…
- Trial name
- VITAL (NCT07847970)
- Testing
- Amlodipine / Valsartan
- Where
- 18 sites in Kazakhstan
- Volunteers
- 216 people
- Sponsor
- VIVA PHARM LLP
Hypertension
Management of Newly Diagnosed and Uncontrolled Hypertension With Fixed-Dose Combination of Perindopril/Amlodipine and Perindopril/Indapamide/Amlodipine
PRECIOUS Study aims to evaluate the efficacy and safety of therapy with fixed-dose combination (FDC) of perindopril/amlodipine (Amlessa®) and FDC of perindopril/indapamide/amlodipine (Co-Amlessa®) on blood pressure reduction in…
- Trial name
- PRECIOUS (NCT03738761)
- Testing
- Amlessa®, Co-Amlessa®
- Where
- 34 sites in Armenia, Croatia and 5 more
- Volunteers
- 471 people
- Sponsor
- KRKA
Hypertension
Study to Evaluate the Efficacy and Safety of Aliskiren Alone and in Combination With Amlodipine in Essential Hypertension
Evaluate the efficacy (blood pressure lowering effect) and safety of aliskiren alone and in combination with amlodipine in patients with essential hypertension.
- Trial name
- NCT00739973
- Testing
- Aliskiren 150 mg tablet, Aliskiren 300 mg tablet, Amlodipine 5 mg capsule
- Where
- 18 sites in United States, Argentina and 16 more
- Volunteers
- 2,694 people
- Sponsor
- Novartis Pharmaceuticals
Healthy
Bioavailability Study of Amlodipine Besylate/Atorvastatin Calcium Tablets 10/80 mg Under Fed Condition
This study is to assess the bioequivalence between Amlodipine besylate/Atorvastatin calcium Tablets 10mg/80mg of Dr. Reddy's Laboratories Limited, India and CADUET® (amlodipine besylate and atorvastatin calcium) tablets 10mg/80mg…
- Trial name
- NCT02292069
- Testing
- Amlodipine besylate/Atorvastatin calcium
- Where
- India
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Dr. Reddy's Laboratories Limited
Hypertension, Hypercholesterolemia
Efficacy and Safety of Ezetimibe/Rosuvastatin and Amlodipine Patients With High Blood Pressure and High Cholesterol
The goal of this clinical trial is to test whether one pill that combines ezetimibe, rosuvastatin, and amlodipine can safely lower cholesterol and blood pressure in Korean adults with high blood pressure and high cholesterol.
- Trial name
- NCT07564726
- Testing
- Amlodipine, Ezetimibe/Rosuvastatin
- Where
- 21 sites in South Korea
- Volunteers
- 163 people
- Sponsor
- Celltrion Pharm, Inc.
Hypertension
Safety and Efficacy of Valsartan Plus Hydrochlorothiazide and Amlodipine in Hypertensive Patients
A double-blind, active-controlled, randomized trial to compare Valsartan plus Hydrochlorothiazide 80mg/12.5mg and Amlodipine 5 mg. Study design: 2 weeks washout, 8 weeks treatment period.
- Trial name
- NCT00426478
- Testing
- Valsartan plus Hydrochlorothiazide (80mg/12.5mg), Amlodipine (5mg)
- Where
- Taiwan
- Volunteers
- 80 people
- Sponsor
- Novartis
Hypertension
Efficacy and Safety of Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Moderate-severe Hypertension
This study evaluated the efficacy (blood pressure lowering effect) and safety of aliskiren/amlodipine/hydrochlorothiazide in patients with moderate to severe hypertension.
- Trial name
- NCT00765674
- Testing
- Aliskiren, Amlodipine, Hydrochlorothiazide (HCTZ)
- Where
- 12 sites in United States, Australia and 10 more
- Volunteers
- 1,191 people
- Sponsor
- Novartis